Pharma BD Deal Intelligence
A heavily backloaded platform alliance: Sosei Heptares took just $26M upfront against over $1B in potential GPCR milestones from Genentech, with only small discovery payments ($3M, then $3.75M) trickling in years later to show the pact is still moving.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Sosei Heptares' multi-target pact with Genentech reinforces the company's position as the go-to GPCR platform partner; Roche's James Sabry called Sosei's…
Sosei Heptares achieved an early discovery milestone under the Genentech collaboration, triggering a $3M payment and signaling that the platform was producing…
Sosei Heptares received a $3.75M payment for progression of a 'potential first-in-class project targeting an undisclosed GPCR' under the Genentech multi-target…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Sosei Heptares and Genentech (Roche) signed a multi-target research collaboration and license agreement leveraging Sosei's StaR/SBDD GPCR drug-design platform. Sosei received $26M in upfront and near-term payments and is eligible for over $1B in research, development and commercial milestones plus royalties. Genentech receives exclusive global rights.
G protein-coupled receptors (GPCRs) are the largest family of cell-surface receptors and the most successful druggable target class in pharma history, accounting for roughly one-third of all FDA-approved drugs. Despite this, hundreds of GPCRs remain underexploited because their structural instability has historically blocked structure-based drug design — the gap Sosei Heptares' StaR platform addresses.
GPCR-focused platforms compete on structural-biology depth, target diversity, and partnership track record. Sosei Heptares is the recognized leader through its StaR (stabilized receptor) technology and structure-based design platform, with prior partnerships spanning Pfizer (up to 10 GPCR targets, oral GLP-1 PF-07081532 reached Phase 2), AstraZeneca, Novartis, Takeda, AbbVie (2020 inflammatory diseases deal), Biohaven, and later Neurocrine ($2.6B biobucks for muscarinic agonists including NBI-1117568) (Pharmaceutical Technology: https://www.pharmaceutical-technology.com/news/sosei-heptares-hits-discovery-milestone-in-gpcr-deal-with-genentech/). Competing GPCR-discovery platforms include Confo Therapeutics (nanobody-stabilized GPCRs), Domain Therapeutics, and ExScientia's AI-augmented design — none has matched Sosei Heptares' breadth of large-pharma deals. The Genentech/Roche agreement extended Sosei's franchise into one of the largest oncology and inflammation pipelines globally, with $26M upfront and >$1B in potential milestones plus royalties for exclusive global rights to nominated targets. The deal validated GPCR platform economics and was followed by recurring milestone payments ($3M, $3.75M) as Genentech advanced first-in-class projects.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / Sosei Group Corporation (Sosei Heptares) (this deal) | 2019 | $1.0B | — |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2019 deals · Roche Holding AG deals · Multiple (undisclosed) deals